The Prostate Cancer Charity has criticised NICE for not recommending the newly licensed chemotherapy drug cabazitaxel as a treatment for men with advanced prostate cancer despite evidence the drug significantly extends the lives of men in the advanced stages of the disease. Commenting on the decision, Owen Sharp, Chief Executive of The Prostate Cancer Charity, explains: “This decision is a huge blow to men living with the very advanced stages of prostate cancer who currently have very limited treatment options open to them. “Cabazitaxel is one of only two licensed drugs available in the UK that offers the hope of precious extra time to men living with advanced prostate cancer. NICE’s decision not to recommend this drug means that men in England and Wales with advanced prostate cancer will find it much harder to access it through the NHS. We are very concerned that this will lead to a postcode lottery and mean some men will not be able to get cabazitaxel in time for it to benefit them.”